Merke DP - Search Results

1

Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenström A, Reisch N, Sandberg DE, Stikkelbroeck NMML, Touraine P, Utari A, Wudy SA, White PC. Claahsen-van der Grinten HL, et al. Among authors: merke dp. Endocr Rev. 2022 Jan 12;43(1):91-159. doi: 10.1210/endrev/bnab016. Endocr Rev. 2022. PMID: 33961029 Free PMC article. Review.

2

A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.

Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB Jr. Laue L, et al. Among authors: merke dp. J Clin Endocrinol Metab. 1996 Oct;81(10):3535-9. doi: 10.1210/jcem.81.10.8855797. J Clin Endocrinol Metab. 1996. PMID: 8855797 Clinical Trial.

3

New approaches to the treatment of congenital adrenal hyperplasia.

Merke DP, Cutler GB Jr. Merke DP, et al. JAMA. 1997 Apr 2;277(13):1073-6. JAMA. 1997. PMID: 9091697 No abstract available.

4

Novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency.

Merke DP, Tajima T, Chhabra A, Barnes K, Mancilla E, Baron J, Cutler GB Jr. Merke DP, et al. J Clin Endocrinol Metab. 1998 Jan;83(1):270-3. doi: 10.1210/jcem.83.1.4513. J Clin Endocrinol Metab. 1998. PMID: 9435454

5

Use of aromatase inhibitors in precocious puberty.

Feuillan P, Merke D, Leschek EW, Cutler GB Jr. Feuillan P, et al. Endocr Relat Cancer. 1999 Jun;6(2):303-6. doi: 10.1677/erc.0.0060303. Endocr Relat Cancer. 1999. PMID: 10731123 Review.

6

New ideas for medical treatment of congenital adrenal hyperplasia.

Merke DP, Cutler GB Jr. Merke DP, et al. Endocrinol Metab Clin North Am. 2001 Mar;30(1):121-35. doi: 10.1016/s0889-8529(08)70022-7. Endocrinol Metab Clin North Am. 2001. PMID: 11344931 Review.

7

Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment.

Merke D, Kabbani M. Merke D, et al. Paediatr Drugs. 2001;3(8):599-611. doi: 10.2165/00128072-200103080-00005. Paediatr Drugs. 2001. PMID: 11577925 Review.

8

Novel basic and clinical aspects of congenital adrenal hyperplasia.

Merke DP, Camacho CA. Merke DP, et al. Rev Endocr Metab Disord. 2001 Aug;2(3):289-96. doi: 10.1023/a:1011520600476. Rev Endocr Metab Disord. 2001. PMID: 11705134 Review. No abstract available.

9

NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Merke DP, Bornstein SR, Avila NA, Chrousos GP. Merke DP, et al. Ann Intern Med. 2002 Feb 19;136(4):320-34. doi: 10.7326/0003-4819-136-4-200202190-00012. Ann Intern Med. 2002. PMID: 11848730 Free article. Review.

10

Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.

Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP. Charmandari E, et al. Among authors: merke dp. J Clin Endocrinol Metab. 2002 May;87(5):2114-20. doi: 10.1210/jcem.87.5.8456. J Clin Endocrinol Metab. 2002. PMID: 11994350

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page